BR9808114A - Horse feed formulation usable to treat epm, processes to treat pm in a horse that needs this treatment, to prevent infection with s. neutrone in horses, and, to exterminate s. neurone in horses - Google Patents
Horse feed formulation usable to treat epm, processes to treat pm in a horse that needs this treatment, to prevent infection with s. neutrone in horses, and, to exterminate s. neurone in horsesInfo
- Publication number
- BR9808114A BR9808114A BR9808114-4A BR9808114A BR9808114A BR 9808114 A BR9808114 A BR 9808114A BR 9808114 A BR9808114 A BR 9808114A BR 9808114 A BR9808114 A BR 9808114A
- Authority
- BR
- Brazil
- Prior art keywords
- horses
- treat
- horse
- epm
- processes
- Prior art date
Links
- 241000283086 Equidae Species 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 6
- 208000015181 infectious disease Diseases 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 abstract 2
- OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 abstract 2
- XQKYUBTUOHHNDV-UHFFFAOYSA-N 2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]-2-(4-fluorophenyl)acetonitrile Chemical compound C1=CC(F)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl XQKYUBTUOHHNDV-UHFFFAOYSA-N 0.000 abstract 2
- 241000146987 Sarcocystis neurona Species 0.000 abstract 2
- 229950005045 letrazuril Drugs 0.000 abstract 2
- 229960000898 toltrazuril Drugs 0.000 abstract 2
- ZSZFUDFOPOMEET-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl ZSZFUDFOPOMEET-UHFFFAOYSA-N 0.000 abstract 1
- 208000005890 Neuroma Diseases 0.000 abstract 1
- QUUTUGLQZLNABV-UHFFFAOYSA-N clazuril Chemical compound C1=CC(Cl)=CC=C1C(C#N)C1=CC=C(N2C(NC(=O)C=N2)=O)C=C1Cl QUUTUGLQZLNABV-UHFFFAOYSA-N 0.000 abstract 1
- 229950003606 clazuril Drugs 0.000 abstract 1
- 229960000248 diclazuril Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"FORMULAçãO DE RAçãO PARA CAVALOS UTILIZáVEL PARA TRATAR EPM, PROCESSOS PARA TRATAR EPM EM UM CAVALO QUE NECESSITA DESTE TRATAMENTO, PARA PREVENIR INFECçãO COM S. NEURONA EM CAVALOS, E, PARA EXTERMINAR S. NEURONA EM CAVALOS". A presente invenção provê formulações úteis para tratar EPM. Provê, também, processos para tratar EPM em um cavalo necessitando deste tratamento, compreendendo administrar uma quantidade farmaceuticamente eficaz de um anti-coccídico baseado em triazina. Prefere-se processos para tratar EPM usando clazuril, diclazuril, toltrazuril ou letrazuril. A presente invenção também provê processos para prevenir infecção com S. neurona em cavalos, compreendendo administrar uma quantidade profilática de um anti-coccídico baseado em triazina. Prefere-se um processo para prevenir infecção com S. neuroma usando clazuril, diclazuril toltrazuril ou letrazuril, sozinho ou com outros terapêuticos conhecidos."FORMULATION OF HORSES FEED USED TO TREAT EPM, PROCESSES TO TREAT EPM IN A HORSE THAT NEEDS THIS TREATMENT, TO PREVENT INFECTION WITH S. NEURONA IN HORSES, AND TO EXTERMINE S. NEURONA IN HORSES". The present invention provides formulations useful for treating EPM. It also provides processes for treating EPM in a horse requiring this treatment, comprising administering a pharmaceutically effective amount of a triazine-based anti-coccidic. Processes for treating EPM using clazuryl, diclazuril, toltrazuril or letrazuril are preferred. The present invention also provides methods for preventing infection with S. neurone in horses, comprising administering a prophylactic amount of a triazine-based anti-coccidic. A process to prevent infection with S. neuroma using clazuril, diclazuryl toltrazuril or letrazuril is preferred, alone or with other known therapies.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4247397P | 1997-03-31 | 1997-03-31 | |
| US08/908,257 US5883095A (en) | 1997-08-07 | 1997-08-07 | Formulations and methods to treat and prevent equine protozoal myeloencephalitis |
| PCT/US1998/006340 WO1998043644A1 (en) | 1997-03-31 | 1998-03-31 | Formulations and methods to treat and prevent equine protozoal myeloencephalitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9808114A true BR9808114A (en) | 2000-03-08 |
Family
ID=26719285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9808114-4A BR9808114A (en) | 1997-03-31 | 1998-03-31 | Horse feed formulation usable to treat epm, processes to treat pm in a horse that needs this treatment, to prevent infection with s. neutrone in horses, and, to exterminate s. neurone in horses |
Country Status (3)
| Country | Link |
|---|---|
| BR (1) | BR9808114A (en) |
| CA (1) | CA2285477C (en) |
| WO (1) | WO1998043644A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747476A (en) | 1996-07-17 | 1998-05-05 | Mortar & Pestle Veterinary Pharmacy, Inc. | Treatment of equine protozoal myeloencephalitis |
| DE19824483A1 (en) | 1998-06-02 | 1999-12-09 | Bayer Ag | Semi-solid aqueous preparations for oral application of toltrazuril sulfone |
| AU773696B2 (en) * | 1998-10-06 | 2004-06-03 | Mars, Incorporated | Animal stereotypy |
| GB9822681D0 (en) * | 1998-10-16 | 1998-12-09 | Vitabiotics Ltd | Method of treatment |
| US6194408B1 (en) * | 1998-12-22 | 2001-02-27 | Bayer Corporation | Triazineone compounds for treating diseases due to Sarcocystis, Neospora and Toxoplasma |
| HK1043065A1 (en) * | 1998-12-22 | 2002-09-06 | 美国拜尔公司 | Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
| US6150361A (en) * | 1998-12-22 | 2000-11-21 | Bayer Corporation | Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
| DE19958388A1 (en) * | 1999-12-03 | 2001-06-07 | Bayer Ag | Triazinone compounds for the treatment of infestations with parasitic protozoa-related diseases |
| US6884797B2 (en) * | 2001-03-30 | 2005-04-26 | Robert F. Hofmann | Targeted oxidative therapeutic formulation |
| US20060240049A1 (en) * | 2003-01-16 | 2006-10-26 | Bart De Spiegeleer | Anti-protozoal compositions comprising diclazuril |
| MX2008009818A (en) * | 2008-07-31 | 2010-02-01 | Avi Mex S A De C V Lab | Coccidiocide combination for veterinary use. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8602342D0 (en) * | 1986-01-30 | 1986-03-05 | Janssen Pharmaceutica Nv | 5 6-dihydro-2-(substituted phenyl)-1 2 4-triazine-3 5(2h 4h)-diones |
-
1998
- 1998-03-31 WO PCT/US1998/006340 patent/WO1998043644A1/en not_active Ceased
- 1998-03-31 CA CA002285477A patent/CA2285477C/en not_active Expired - Lifetime
- 1998-03-31 BR BR9808114-4A patent/BR9808114A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2285477A1 (en) | 1998-10-08 |
| CA2285477C (en) | 2006-10-10 |
| WO1998043644A1 (en) | 1998-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE144420T1 (en) | USE OF RILUZOLE TO TREAT PARKINSON'S AND PARKINSON'S SYNDROMES | |
| BR9815357A (en) | Pharmaceutical composition, processes to prevent or treat a disease, to prevent or treat alzheimer's disease in a patient, to evaluate the effectiveness of an alzheimer's treatment process in a patient, to monitor alzheimer's disease or susceptibility to it in a patient, use of a * peptide or an antibody thereof, composition, and set of diagnoses for monitoring the treatment of alzheimer's disease | |
| BR0109446A (en) | Medication for intracorporeal application, use of a halogenated xanthene, pharmaceutical composition, and method of treatment | |
| AU1865100A (en) | Hyaluronate lyase used for promoting penetration in topical agents | |
| BR9715022A (en) | Method for treating prostate disease using systematic and / or prolonged release of vitamin D formulations | |
| ATE228832T1 (en) | SYSTEM FOR THE TARGETED DELIVERY OF ACTIVE INGREDIENTS, METHOD FOR THE PRODUCTION AND USE THEREOF | |
| BR9808114A (en) | Horse feed formulation usable to treat epm, processes to treat pm in a horse that needs this treatment, to prevent infection with s. neutrone in horses, and, to exterminate s. neurone in horses | |
| BR0209658A (en) | 4-Amino-5-phenyl-7-1-cyclobutyl-pyrrolo [2,3-d] pyrimidine derivatives | |
| BR0317747A (en) | Method of concomitant therapeutic treatment of an individual, pharmaceutical composition, kit, use of a first agent and a second agent, and methods of preventing or treating amyloid-b-related disease, alzheimer's disease and mild cognitive impairment | |
| ATE146677T1 (en) | PHARMACEUTICAL FORMULATION FOR TREATING NICOTINE DEPENDENCE | |
| ATE233091T1 (en) | USE OF HISTAMINE-2 AGONISTS TO TREAT SEXUAL DISORDERS | |
| BR9708287A (en) | Process for treating or preventing a central nervous system disorder in a human, for eliciting an antiemetic effect in a human being and for treating a disease state in a human, pharmaceutical composition for treating central nervous system disorders in a human being human, and, pharmaceutical unit dosage form | |
| NL300330I2 (en) | Preparation for delivering peptides | |
| ATE267583T1 (en) | MEDICINAL PREPARATIONS FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISORDERS | |
| BR9810981A (en) | Yohimbine and arginine-containing medication to treat erectile dysfunction | |
| DE69800859D1 (en) | Use of moxonidine to treat neuropathic pain | |
| MX9804343A (en) | Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags) | |
| BR0317772A (en) | Method of treating a behavioral disorder, use of a compound, and therapeutic agent for a behavioral disorder | |
| ATE490780T1 (en) | HUMAN GROWTH HORMONE FOR THE TREATMENT OF ANOREXIA NERVOSA | |
| BR9714625A (en) | Composition and use of it. | |
| James | Neuropathy: nutritional prevention/treatment suggested | |
| ECSP951424A (en) | PROCEDURE FOR THE ADMINISTRATION OF AZYTHROMYCIN | |
| RU95106897A (en) | Psoriasis treatment method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Technical examination (opinion): publication of technical examination (opinion) | ||
| B07A | Technical examination (opinion): publication of technical examination (opinion) | ||
| B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law | ||
| B09B | Decision: refusal |
Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO APRESENTA SUFICIENCIA DESCRITIVA ( ART. 24 DA LPI ); AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO ( ART. 25 DA LPI ) |
|
| B09B | Decision: refusal |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |